Li Y, Tong X, Huang L, et al. - Given Moreau score has been employed to distinguish chronic lymphocytic leukemia (CLL) from other mature B-cell neoplasms but it displayed limitations in Asian patients, thus, researchers tried a new score system substituting CD5 and CD23 with CD43 and CD180 to assess its diagnostic value of CLL. They used 237 untreated samples diagnosed with mature B-cell neoplasms. All samples were analyzed for expression of CD5, CD19, CD20, CD23, CD43, CD79b, CD180, CD200, FMC7, and surface immunoglobulin. On the basis of the logistic regression model, a proposed score was built. The new CLL score incorporated CD43/CD180, CD200, FMC7, and CD79b, and yielded a sensitivity of 91.8% and a specificity of 83.1%. In the validation cohort, these findings were corroborated with a sensitivity of 90.5% and a specificity of 79.5%. Overall, an accurate differentiation of CLL from non-CLL was allowed by this proposed atypical CLL score together with morphological and molecular methods, especially in Chinese patients exhibiting atypical immunophenotype.